Literature DB >> 11440640

Combined sequential treatment with interferon and dsRNA abrogates virus resistance to interferon action.

P I Marcus1, M J Sekellick.   

Abstract

Many viruses have evolved mechanisms to resist the action of interferon (IFN). These include production of viral gene products that sequester double-stranded RNA (dsRNA) and of small helical RNA. These potentially prevent activation of dsRNA-dependent pathways of IFN action or block expression of cellular genes activated exclusively by dsRNA that may contribute to the antiviral state. Thus, dsRNA might be rate limiting in the development of an IFN-mediated antiviral state. In support of this hypothesis, dsRNA added exogenously to IFN-treated cells in the form of poly(rI):poly(rC) is shown to establish in a dose-dependent manner an antiviral state against two viruses otherwise highly refractory to IFN action, avian reovirus (ARV) and Newcaste disease virus (NDV). Cells exposed singly to high doses of IFN or dsRNA reduced the plaque-forming capacity of these viruses on chicken embryo cells 2-fold. When used in combination, there was up to a 100-fold reduction. In order to abrogate IFN resistance, dsRNA must be added after, not before, an IFN-mediated latent antiviral state is established. dsRNA added exogenously is thought to achieve the threshold required for activation of dsRNA-dependent pathways of IFN action or to induce some dsRNA-stimulated gene whose product acts synergistically with that of some IFN-stimulated gene. The combined sequential treatment with IFN and dsRNA may be useful in overcoming the anti-IFN activity of viruses of clinical interest or in other clinical conditions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11440640     DOI: 10.1089/107999001750277907

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  7 in total

1.  Co-administration of toll-like receptor (TLR)-3 and 4 ligands augments immune response to Newcastle disease virus (NDV) vaccine in chicken.

Authors:  T R Kannaki; E Priyanka; M R Reddy
Journal:  Vet Res Commun       Date:  2019-08-24       Impact factor: 2.459

2.  Identification and characterization of a functional, alternatively spliced Toll-like receptor 7 (TLR7) and genomic disruption of TLR8 in chickens.

Authors:  Victoria J Philbin; Muhammad Iqbal; Yvonne Boyd; Marianne J Goodchild; Richard K Beal; Nat Bumstead; John Young; Adrian L Smith
Journal:  Immunology       Date:  2005-04       Impact factor: 7.397

3.  Identification and functional characterization of chicken toll-like receptor 5 reveals a fundamental role in the biology of infection with Salmonella enterica serovar typhimurium.

Authors:  Muhammad Iqbal; Victoria J Philbin; G S K Withanage; Paul Wigley; Richard K Beal; Marianne J Goodchild; Paul Barrow; Ian McConnell; Duncan J Maskell; John Young; Nat Bumstead; Yvonne Boyd; Adrian L Smith
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

4.  Interferon induction and/or production and its suppression by influenza A viruses.

Authors:  Philip I Marcus; Jillian M Rojek; Margaret J Sekellick
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  Amelioration of influenza virus pathogenesis in chickens attributed to the enhanced interferon-inducing capacity of a virus with a truncated NS1 gene.

Authors:  Angela N Cauthen; David E Swayne; Margaret J Sekellick; Philip I Marcus; David L Suarez
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

6.  Inducible, reversible, and stable RNA interference in mammalian cells.

Authors:  Sunita Gupta; Rebecca A Schoer; James E Egan; Gregory J Hannon; Vivek Mittal
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-04       Impact factor: 11.205

7.  Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons.

Authors:  Robert E Lanford; Bernadette Guerra; Helen Lee; Devron R Averett; Brad Pfeiffer; Deborah Chavez; Lena Notvall; Catherine Bigger
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.